Patents by Inventor Mikko PASSINIEMI

Mikko PASSINIEMI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS
    Publication number: 20210347765
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5, R23, R24, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.
    Type: Application
    Filed: July 6, 2021
    Publication date: November 11, 2021
    Inventors: David DIN BELLE, Mikko Mäkelä, Mikko Passiniemi, Pekka Pietikäinen, Petteri Rummakko, Eija Tiainen, Matti Vaismaa, Gerd Wohlfahrt
  • Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors
    Patent number: 11098032
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5, R23, R24, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: August 24, 2021
    Assignee: ORION CORPORATION
    Inventors: David Din Belle, Mikko Mäkelä, Mikko Passiniemi, Pekka Pietikäinen, Petteri Rummakko, Eija Tiainen, Matti Vaismaa, Gerd Wohlfahrt
  • PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS
    Publication number: 20200299280
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5, R23, R24, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.
    Type: Application
    Filed: June 8, 2020
    Publication date: September 24, 2020
    Inventors: David DIN BELLE, Mikko MÄKELÄ, Mikko PASSINIEMI, Pekka PIETIKÄINEN, Petteri RUMMAKKO, Eija TIAINEN, Matti VAISMAA, Gerd WOHLFAHRT
  • Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors
    Patent number: 10717726
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5, R23, R24, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: July 21, 2020
    Assignee: ORION CORPORATION
    Inventors: David Din Belle, Mikko Mäkelä, Mikko Passiniemi, Pekka Pietikäinen, Petteri Rummakko, Eija Tiainen, Matti Vaismaa, Gerd Wohlfahrt
  • PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS
    Publication number: 20190359601
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5, R23, R24, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.
    Type: Application
    Filed: December 21, 2017
    Publication date: November 28, 2019
    Inventors: David DIN BELLE, Mikko MÄKELÄ, Mikko PASSINIEMI, Pekka PIETIKÄINEN, Petteri RUMMAKKO, Eija TIAINEN, Matti VAISMAA, Gerd WOHLFAHRT
  • CYP17 inhibitors/antiandrogens
    Patent number: 9890139
    Abstract: Compounds of formula (I) wherein R1 to R8, A, B, Z1, and Z2 are as defined in the claims and pharmaceutically acceptable salts and esters thereof are disclosed. The compounds of formula (I) possess utility as androgen receptor antagonists (inhibitors) and/or cytochrome P450 monooxygenase 17?-hydroxylase/17,20-lyase (CYP17) inhibitors. The compounds are useful as medicaments in the treatment of cancer, particularly prostate cancer, and other androgen dependent conditions and diseases where androgen antagonism is desired.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: February 13, 2018
    Assignee: ORION CORPORATION
    Inventors: Gerd Wohlfahrt, Petteri Rummakko, Arja Karjalainen, Mikko Passiniemi, Pekka Pietikäinen, Anssi Haikarainen, Emilia Väisänen, Eija Tiainen
  • NOVEL CYP17 INHIBITORS/ANTIANDROGENS
    Publication number: 20160130254
    Abstract: Compounds of formula (I) wherein R1 to R8, A, B, Z1, and Z2 are as defined in the claims and pharmaceutically acceptable salts and esters thereof are disclosed. The compounds of formula (I) possess utility as androgen receptor antagonists (inhibitors) and/or cytochrome P450 monooxygenase 17?-hydroxylase/17,20-lyase (CYP17) inhibitors. The compounds are useful as medicaments in the treatment of cancer, particularly prostate cancer, and other androgen dependent conditions and diseases where androgen antagonism is desired.
    Type: Application
    Filed: June 10, 2014
    Publication date: May 12, 2016
    Inventors: Gerd WOHLFAHRT, Petteri RUMMAKKO, Arja KARJALAINEN, Mikko PASSINIEMI, Pekka PIETIKÄINEN, Anssi HAIKARAINEN, Emilia VÄISÄNEN, Eija TIAINEN